Blood and sputum biomarkers in COPD and asthma: a review

G Paone, V. Leone, V Conti, Loredana De Marchis, E. Ialleni, C. Graziani, M. Salducci, M Ramaccia, G Munafò

Research output: Contribution to journalArticle

11 Downloads (Pure)

Abstract

Chronic obstructive pulmonary disease (COPD) and asthma are lung inflammatory diseases that represent major public health problems. The primary, and often unique, method to evaluate lung function is spirometry, which reflects disease severity rather than disease activity. Moreover, its measurements strictly depend on patient's compliance, physician's expertise and data interpretation. The limitations of clinical history and pulmonary function tests have encouraged focusing on new possible tracers of diseases. The increase of the inflammatory response in the lungs represents an early pathological event, so biological markers related to inflammation may play key roles in earlier diagnosis, evaluation of functional impairment and prognosis. Biomarkers are measurable indicators associated with the presence and/or severity of a biological or pathogenic process, which may predict functional impairment, prognosis and response to therapy. The traditional approach based on invasive techniques (bronchoalveolar lavage and biopsies) may be replaced, at least in part, by using less invasive methods to collect specimens (sputum and blood), in which biomarkers could be measured. Proteomics, by the association between different protein profiles and pathogenic processes, is gaining an important role in pulmonary medicine allowing a more precise discrimination between patients with different outcomes and response to therapy. The aim of this review was to evaluate the use of biomarkers of airway inflammation in the context of both research and clinical practice.

Original languageEnglish
Pages (from-to)698-708
Number of pages11
JournalEuropean Review for Medical and Pharmacological Sciences
Volume20
Issue number4
Publication statusPublished - 2016

Fingerprint

Sputum
Chronic Obstructive Pulmonary Disease
Asthma
Biomarkers
Inflammation
Pulmonary Medicine
Lung
Spirometry
Respiratory Function Tests
Bronchoalveolar Lavage
Patient Compliance
Proteomics
Lung Diseases
Early Diagnosis
Public Health
Physicians
Biopsy
Therapeutics
Research
Proteins

Keywords

  • Animals
  • Asthma
  • Biomarkers
  • Biopsy
  • Bronchoalveolar Lavage
  • Humans
  • Inflammation Mediators
  • Prognosis
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory Function Tests
  • Spirometry
  • Sputum
  • Journal Article
  • Review

Cite this

Paone, G., Leone, V., Conti, V., De Marchis, L., Ialleni, E., Graziani, C., ... Munafò, G. (2016). Blood and sputum biomarkers in COPD and asthma: a review. European Review for Medical and Pharmacological Sciences, 20(4), 698-708.

Blood and sputum biomarkers in COPD and asthma : a review. / Paone, G; Leone, V.; Conti, V; De Marchis, Loredana; Ialleni, E.; Graziani, C.; Salducci, M.; Ramaccia, M; Munafò, G.

In: European Review for Medical and Pharmacological Sciences, Vol. 20, No. 4, 2016, p. 698-708.

Research output: Contribution to journalArticle

Paone, G, Leone, V, Conti, V, De Marchis, L, Ialleni, E, Graziani, C, Salducci, M, Ramaccia, M & Munafò, G 2016, 'Blood and sputum biomarkers in COPD and asthma: a review', European Review for Medical and Pharmacological Sciences, vol. 20, no. 4, pp. 698-708.
Paone G, Leone V, Conti V, De Marchis L, Ialleni E, Graziani C et al. Blood and sputum biomarkers in COPD and asthma: a review. European Review for Medical and Pharmacological Sciences. 2016;20(4):698-708.
Paone, G ; Leone, V. ; Conti, V ; De Marchis, Loredana ; Ialleni, E. ; Graziani, C. ; Salducci, M. ; Ramaccia, M ; Munafò, G. / Blood and sputum biomarkers in COPD and asthma : a review. In: European Review for Medical and Pharmacological Sciences. 2016 ; Vol. 20, No. 4. pp. 698-708.
@article{e63a8009442d4648b90df0afc06d8f22,
title = "Blood and sputum biomarkers in COPD and asthma: a review",
abstract = "Chronic obstructive pulmonary disease (COPD) and asthma are lung inflammatory diseases that represent major public health problems. The primary, and often unique, method to evaluate lung function is spirometry, which reflects disease severity rather than disease activity. Moreover, its measurements strictly depend on patient's compliance, physician's expertise and data interpretation. The limitations of clinical history and pulmonary function tests have encouraged focusing on new possible tracers of diseases. The increase of the inflammatory response in the lungs represents an early pathological event, so biological markers related to inflammation may play key roles in earlier diagnosis, evaluation of functional impairment and prognosis. Biomarkers are measurable indicators associated with the presence and/or severity of a biological or pathogenic process, which may predict functional impairment, prognosis and response to therapy. The traditional approach based on invasive techniques (bronchoalveolar lavage and biopsies) may be replaced, at least in part, by using less invasive methods to collect specimens (sputum and blood), in which biomarkers could be measured. Proteomics, by the association between different protein profiles and pathogenic processes, is gaining an important role in pulmonary medicine allowing a more precise discrimination between patients with different outcomes and response to therapy. The aim of this review was to evaluate the use of biomarkers of airway inflammation in the context of both research and clinical practice.",
keywords = "Animals, Asthma, Biomarkers, Biopsy, Bronchoalveolar Lavage, Humans, Inflammation Mediators, Prognosis, Pulmonary Disease, Chronic Obstructive, Respiratory Function Tests, Spirometry, Sputum, Journal Article, Review",
author = "G Paone and V. Leone and V Conti and {De Marchis}, Loredana and E. Ialleni and C. Graziani and M. Salducci and M Ramaccia and G Munaf{\`o}",
year = "2016",
language = "English",
volume = "20",
pages = "698--708",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "4",

}

TY - JOUR

T1 - Blood and sputum biomarkers in COPD and asthma

T2 - a review

AU - Paone, G

AU - Leone, V.

AU - Conti, V

AU - De Marchis, Loredana

AU - Ialleni, E.

AU - Graziani, C.

AU - Salducci, M.

AU - Ramaccia, M

AU - Munafò, G

PY - 2016

Y1 - 2016

N2 - Chronic obstructive pulmonary disease (COPD) and asthma are lung inflammatory diseases that represent major public health problems. The primary, and often unique, method to evaluate lung function is spirometry, which reflects disease severity rather than disease activity. Moreover, its measurements strictly depend on patient's compliance, physician's expertise and data interpretation. The limitations of clinical history and pulmonary function tests have encouraged focusing on new possible tracers of diseases. The increase of the inflammatory response in the lungs represents an early pathological event, so biological markers related to inflammation may play key roles in earlier diagnosis, evaluation of functional impairment and prognosis. Biomarkers are measurable indicators associated with the presence and/or severity of a biological or pathogenic process, which may predict functional impairment, prognosis and response to therapy. The traditional approach based on invasive techniques (bronchoalveolar lavage and biopsies) may be replaced, at least in part, by using less invasive methods to collect specimens (sputum and blood), in which biomarkers could be measured. Proteomics, by the association between different protein profiles and pathogenic processes, is gaining an important role in pulmonary medicine allowing a more precise discrimination between patients with different outcomes and response to therapy. The aim of this review was to evaluate the use of biomarkers of airway inflammation in the context of both research and clinical practice.

AB - Chronic obstructive pulmonary disease (COPD) and asthma are lung inflammatory diseases that represent major public health problems. The primary, and often unique, method to evaluate lung function is spirometry, which reflects disease severity rather than disease activity. Moreover, its measurements strictly depend on patient's compliance, physician's expertise and data interpretation. The limitations of clinical history and pulmonary function tests have encouraged focusing on new possible tracers of diseases. The increase of the inflammatory response in the lungs represents an early pathological event, so biological markers related to inflammation may play key roles in earlier diagnosis, evaluation of functional impairment and prognosis. Biomarkers are measurable indicators associated with the presence and/or severity of a biological or pathogenic process, which may predict functional impairment, prognosis and response to therapy. The traditional approach based on invasive techniques (bronchoalveolar lavage and biopsies) may be replaced, at least in part, by using less invasive methods to collect specimens (sputum and blood), in which biomarkers could be measured. Proteomics, by the association between different protein profiles and pathogenic processes, is gaining an important role in pulmonary medicine allowing a more precise discrimination between patients with different outcomes and response to therapy. The aim of this review was to evaluate the use of biomarkers of airway inflammation in the context of both research and clinical practice.

KW - Animals

KW - Asthma

KW - Biomarkers

KW - Biopsy

KW - Bronchoalveolar Lavage

KW - Humans

KW - Inflammation Mediators

KW - Prognosis

KW - Pulmonary Disease, Chronic Obstructive

KW - Respiratory Function Tests

KW - Spirometry

KW - Sputum

KW - Journal Article

KW - Review

M3 - Article

C2 - 26957273

VL - 20

SP - 698

EP - 708

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 4

ER -